Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
248.93
-0.08 (-0.03%)
At close: Nov 3, 2026, 4:00 PM EST
248.93
0.00 (0.00%)
After-hours: Nov 3, 2026, 7:30 PM EST
Biogen Stock Forecast
Stock Price Forecast
According to 36 analysts polled by S&P Global, Biogen stock has a consensus rating of "Buy" and an average price target of $264.82. The average 1-year stock price forecast is 6.38% higher than the current stock price, while the lowest is $175 (-29.70%) and the highest is $325 (+30.56%).
Price Target: $264.82 (+6.38%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Biogen stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 18 | 20 | 20 | 19 | 21 | 21 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 14 | 12 | 11 | 12 | 10 | 10 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 36 | 36 | 35 | 35 | 36 | 36 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Hold Maintains $250 | Hold | Maintains | $250 | +0.43% | Nov 2, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $251 → $270 | Buy | Reiterates | $251 → $270 | +8.46% | Nov 2, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $280 → $300 | Buy | Maintains | $280 → $300 | +20.52% | Nov 2, 2026 |
| Truist Financial | Truist Financial | Buy Maintains $235 → $260 | Buy | Maintains | $235 → $260 | +4.45% | Oct 30, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $242 → $286 | Buy | Maintains | $242 → $286 | +14.89% | Oct 30, 2026 |
Financial Forecast
Revenue This Year
10.53B
from 9.89B
Increased by 6.46%
Revenue Next Year
10.76B
from 10.53B
Increased by 2.22%
EPS This Year
12.52
from 15.28
Decreased by -18.07%
EPS Next Year
16.26
from 12.52
Increased by 29.90%
EPS and Forward PE are based on non-GAAP adjusted numbers.